<DOC>
	<DOCNO>NCT00631059</DOCNO>
	<brief_summary>The objective protocol collect leukemia cell specimens adult ( 18 year age ) diagnose acute leukemia time initial diagnosis , applicable , time first relapse . These specimen , conjunction de-identified data set , utilized prospectively determine potential chemotherapy resistance patient population . The specific aim study follow : To collect peripheral blood specimen patient diagnose acute leukemia time initial diagnosis , applicable , time first relapse To evaluate leukemia cell blood specimen chemotherapy resistance utilize Hem ( A ) + technology To develop body evidence acute leukemia patient demonstrate applicability Hem ( A ) + assay determine following : Predict responder non-responders common chemotherapeutic agent Track treatment result comparison prediction result assay Identify optimal chemotherapy dose patient Identify efficacious pharmaceutical agent combination</brief_summary>
	<brief_title>Assessment Determination Chemotherapy Resistance Newly-Diagnosed First Relapse Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>Newly Diagnosed Subjects The subject male female , age 18 year age older The subject diagnosis acute lymphocytic leukemia ( ALL ) acute myelogenous leukemia ( AML ) ; subject must pathologyconfirmed diagnosis The subject must pathologyconfirmed diagnosis Acute lymphocytic leukemia ( ALL ) acute myelogenous leukemia ( AML ) define &gt; 25 % blast bone marrow and/or peripheral blood The subject receive chemotherapy treatment acute leukemia prior initial study visit The subject able willing provide write informed consent The subject able understand study cooperate study instruction Relapsed Subjects The subject male female , age 18 year age older The subject diagnosis relapse acute lymphocytic leukemia ( ALL ) relapse acute myelogenous leukemia ( AML ) The subject must pathologyconfirmed diagnosis Acute lymphocytic leukemia ( ALL ) acute myelogenous leukemia ( AML ) define â‰¥ 25 % blast bone marrow and/or peripheral blood The subject receive one preidentified chemotherapeutic agent treatment initial acute leukemia diagnosis The subject receive systemic chemotherapy treatment relapse acute leukemia Receipt intrathecal chemotherapy permissible The subject able willing provide write informed consent The subject able understand study cooperate study instructions The subject uncontrolled serious medical psychiatric illness , opinion investigator , would compromise subject 's safety collection data The subject receive treatment investigational drug within two week initial subsequent study visit Subjects age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Hitachi</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Relapse</keyword>
	<keyword>Chemotherapy Resistance</keyword>
</DOC>